Monitoring PTP4A3 expression levels and STAT3 phosphorylation status in tumor tissues could be implemented to indicate personalized phosphatase inhibitor treatment for ovarian cancer (Lazo et al., 2023). This evidence concerns the gene PTP4A3 and ovarian carcinoma.